Voyager Therapeutics Valuation Multiples

Voyager Therapeutics Overview

About Voyager Therapeutics

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Founded

2013

HQ

Employees

172

Website

voyagertherapeutics.com

Sectors

BiopharmaceuticalsBioTechDeepTech

Financials (LTM)

Revenue: $43M

EBITDA: ($124M)

EV

$216M

Valuation Multiples

Multiples.vc

Start free trial

Voyager Therapeutics Financials

Voyager Therapeutics reported last 12-month revenue of $43M and negative EBITDA of ($124M).

In the same LTM period, Voyager Therapeutics generated $43M in gross profit, ($124M) in EBITDA losses, and had net loss of ($120M).

Voyager Therapeutics P&L

In the most recent fiscal year, Voyager Therapeutics reported revenue of $40M and EBITDA of ($127M).

Voyager Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

Voyager Therapeutics Stock Performance

Voyager Therapeutics has current market cap of $231M, and enterprise value of $216M.

Voyager Therapeutics' stock price is $4.15.

Voyager Therapeutics Valuation Multiples

Voyager Therapeutics trades at 5.0x EV/Revenue multiple, and (1.7x) EV/EBITDA.

Voyager Therapeutics Financial Valuation Multiples

As of March 21, 2026, Voyager Therapeutics has market cap of $231M and EV of $216M.

Equity research analysts estimate Voyager Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Voyager Therapeutics has a P/E ratio of (1.9x).

Voyager Therapeutics Margins & Growth Rates

Voyager Therapeutics' revenue in the last 12 month grew by 25%.

Voyager Therapeutics' revenue per employee in the last FY averaged $0.3M.

Voyager Therapeutics' rule of 40 is (262%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Voyager Therapeutics' rule of X is (224%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Voyager Therapeutics Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Voyager Therapeutics M&A Activity

Voyager Therapeutics acquired XXX companies to date.

Last acquisition by Voyager Therapeutics was on XXXXXXXX, XXXXX. Voyager Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Voyager Therapeutics Investment Activity

Voyager Therapeutics invested in XXX companies to date.

Voyager Therapeutics made its latest investment on XXXXXXXX, XXXXX. Voyager Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).